

Review of: "Why Non-HDL Cholesterol is Preferred over Apolipoprotein B-100 (Apo B)"

Jie Xu

Potential competing interests: No potential competing interests to declare.

1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias suggest Non-HDL-C evaluation is recommended for risk assessment, particularly in people with high TG levels, DM, obesity, or very low LDL-C levels (Class I recommendation, Level C evidence). I believe this should be mentioned in the discussion part.
2. Please re-check the spelling mistakes, like "ASCD".
3. The correct abbreviation terms should be ApoB (not apoB), ApoB-100, non-HDL-C, HDL-C, LDL-C, TC. This needs to be corrected in the figures as well as the text.
4. I prefer the baseline data should be present.
5. Is the main outcomes ASCVD (defined in the article)? It should be elucidated more clearly in the "Method" part.
6. The table should be re-designed. I suggest the table and figures title should be more clear, for example: ROC curves of different lipoprotein parameters for distinguishing ASCVD from normal.